Q1 Earnings Estimate for AVTX Issued By HC Wainwright

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Avalo Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($1.06) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2025 earnings at ($1.09) EPS and Q3 2025 earnings at ($1.13) EPS.

Several other brokerages have also issued reports on AVTX. BTIG Research started coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a “buy” rating and a $40.00 price target for the company. Wedbush restated an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Piper Sandler started coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Trading Down 0.4 %

Shares of NASDAQ:AVTX opened at $7.63 on Monday. Avalo Therapeutics has a 52-week low of $4.60 and a 52-week high of $34.46. The firm has a fifty day moving average of $7.47 and a 200 day moving average of $9.13.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AVTX. Ikarian Capital LLC boosted its holdings in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares during the period. RA Capital Management L.P. bought a new stake in Avalo Therapeutics in the third quarter valued at approximately $9,186,000. Geode Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after purchasing an additional 94,742 shares during the period. Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $446,000. Finally, Walleye Capital LLC bought a new position in shares of Avalo Therapeutics in the fourth quarter worth approximately $145,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.